Neuroleptic Malignant Syndrome: Pathophysiology, Diagnosis & Treatment

Dantrolene antagonizes ryanodine receptors to reduce calcium release from sarcoplasmic reticulum, with 15-hour half-life. Contraindicated in hepatic dysfunction and with calcium antagonists. A systematic review of 450 patients showed zero mortality with electroconvulsive therapy but higher mortality with dantrolene, though this may reflect patient severity. Analysis showed no statistically significant mortality differences overall, but in severe cases, dantrolene, bromocriptine, and electroconvulsive therapy significantly reduced mortality. For mild-moderate cases, symptomatic management alone suffices. Prevention requires waiting >2 weeks before restarting antipsychotics, using low-potency agents, and avoiding lithium and dehydration. Recurrence occurs in approximately 2% of cases.

NMS management requires immediate cessation of the offending medication and exclusion of infectious etiologies. Pharmacologic treatment includes dantrolene (1-2.5 mg/kg every 6-8 hours, max 10 mg/kg/day) as a direct muscle relaxant blocking ryanodine receptors; bromocryptine (2.5 mg every 6-8 hours, max 40 mg/day) as a dopamine agonist; and amantadine (200 mg every 12 hours) as an alternative dopamine agonist. Adjunctive therapies include benzodiazepines (lorazepam, diazepam) for agitation and muscle relaxation, and alpha-2 agonists for autonomic instability. Supportive care is essential, including hemodynamic support with vasopressors/antihypertensives, temperature management with cooling devices, and prevention/treatment of acute kidney injury. Complications include rhabdomyolysis, DIC, renal failure, and coma. ECT may be indicated for refractory cases, though it carries higher complication risks in NMS patients.

Neuroleptic malignant syndrome (NMS) is a life-threatening extrapyramidal side effect caused by D2 receptor blockade. Clinical features include high-grade fever, severe muscle rigidity, autonomic instability, altered sensorium, and elevated CPK. Immediate management requires stopping the antipsychotic and administering dantrolene (ryanodine receptor blocker) plus bromocriptine (D2 agonist). Bromocriptine is most specific as it reverses the underlying D2 blockade, though it may temporarily worsen psychosis. The priority is saving the patient's life, making this condition a medical emergency requiring immediate intervention.

Treatment for NMS involves discontinuing the offending antipsychotic medication. Two medications can be used: bromocriptine (a D2 receptor agonist) or dantrolene (a muscle relaxant). Bromocriptine works by stimulating dopamine receptors, while dantrolene directly relaxes skeletal muscles. Understanding which medication is which is important for exam questions.

Treatment depends on severity: (1) Mild NMS: Benzodiazepines such as lorazepam (1-2 mg IV/IM every 6 hours) or diazepam (10 mg every 8 hours); (2) Moderate NMS: Bromocriptine (2.5 mg every 8 hours) or amantadine (200-400 mg daily in divided doses); (3) Severe NMS: Dantrolene IV infusion (1-2.5 mg/kg initial dose, followed by 1 mg/kg every 6 hours). Dantrolene works by inhibiting calcium release from the endoplasmic reticulum, decreasing intracellular calcium availability and reducing muscle rigidity. If antidote therapy fails, electroconvulsive therapy (ECT) may be considered as a last resort, sometimes administered concurrently with dantrolene for severe rigidity.

Evidence for NMS treatment is limited to case reports and series due to the condition's rarity and severity. Treatment should be severity-appropriate: mild cases respond to benzodiazepines; moderate cases require bromocriptine or amantadine; severe cases require dantrolene and ECT. Reintroduction of antipsychotics after NMS requires waiting at least 15 days, using an agent with lower D2 affinity, starting at low doses, and monitoring closely as recurrence can occur in up to 4% of patients. The case demonstrates that poor response to multiple antipsychotics may indicate treatment-resistant schizophrenia requiring clozapine.

NMS carries approximately 10% mortality risk with potential complications including renal failure, cardiac dysfunction, respiratory failure, and cognitive sequelae from prolonged hypoxia. Management requires immediate antipsychotic cessation, aggressive supportive care for hyperthermia, and intensive care monitoring. After acute resolution, patients should wait 2-4 weeks before restarting antipsychotics, beginning at very low doses with gradual titration while avoiding concurrent lithium. Approximately 30% of patients cannot tolerate antipsychotics long-term. Prevention remains paramount through vigilance, early recognition, and appropriate clinical protocols, as early intervention prevents life-threatening complications.

NMS is the most fatal side effect of antipsychotic medications, characterized by fever plus muscle rigidity/spasms. Management requires immediate discontinuation of the medication and notification of the physician. Prevention involves proper hydration of patients.

Neuroleptic Malignant Syndrome (NMS) is a rare but serious condition associated with antipsychotic medications, characterized by muscle rigidity, fever, autonomic instability, and altered mental status. NMS is associated specifically with antipsychotic drugs, not antidepressants, mood stabilizers, or anxiolytics. Management involves immediately stopping the causative antipsychotic medication and providing supportive care including monitoring vital signs, managing fever, and addressing autonomic instability. Anticholinergic medications may be used to help manage symptoms.

Neuroleptic Malignant Syndrome (NMS) is a rare but life-threatening idiosyncratic reaction to antipsychotic medications, characterized by a distinctive clinical syndrome of altered mental status, muscle rigidity, fever, and autonomic instability; it typically occurs within 1-4 weeks of starting or increasing antipsychotic doses, and requires immediate discontinuation of the offending medication along with supportive care and specific antidotes like dantrolene or bromocriptine, with a mortality rate of approximately 15-20% despite modern treatment.

Rhabdomyolysis represents a critical condition where skeletal muscle destruction releases intracellular contents into circulation, causing myoglobinuria and potentially AKI. Causes include crush injuries, burns, electrical injuries, drug use, infections, ischemia, compartment syndrome, and medications (corticosteroids, statins, isoniazid). Clinical features include myalgia, weakness, malaise, dark urine, and metabolic disturbances, though patients may present without alarming symptoms. Laboratory investigation centers on creatine kinase (CK >5-fold increase is significant), with myoglobin elevation preceding CK and causing characteristic reddish-brown urine. Metabolic complications include hyperkalemia, hypocalcemia, hyperphosphatemia, and hyperuricemia. Emergency management emphasizes immediate IV hydration starting at the scene (1L/hr saline initially, then alternating with dextrose saline), continued hydration for 24-48 hours, and careful electrolyte management with calcium gluconate and ion exchange resins for hyperkalemia. The McMahon score predicts death or dialysis risk by incorporating calcium, CK, phosphate, bicarbonate levels, etiology, and age—scores >10 indicate 52% risk of renal replacement therapy or death.

This concluding section covers acute kidney injury and rhabdomyolysis. Acute kidney injury represents an abrupt, often reversible decline in glomerular filtration rate causing elevated BUN and creatinine, with symptoms including oliguria, edema, weight gain, lethargy, nausea, and anorexia lasting 7-21 days. Diagnostic criteria include serum creatinine increase of ≥0.3 mg/dL within 48 hours, ≥50% increase within 7 days, or urine output <0.5 mL/kg/hour for >6 hours. Laboratory monitoring includes serum creatinine (potentially falsely elevated in low muscle mass), creatinine clearance (24-hour urine evaluating proteinuria and microalbuminuria), and eGFR (normal >60, abnormal <60, chronic kidney disease <60 for ≥3 months). Rhabdomyolysis is a life-threatening syndrome of muscle necrosis releasing contents into circulation, commonly causing acute kidney injury. Risk factors include crush injuries, high-dose statins, excessive alcohol, extreme exercise, and high fever. Classic presentation includes myalgia, muscle weakness, and tea-colored urine, with CK levels typically ≥5 times upper limit of normal. This is an emergency requiring ER referral as fasciotomy may be necessary.

Diagnosis uses a structured approach: bedside ECG for hypokalemia, urine dipstick (may be misleading), venous blood gas for electrolytes, CBC, U&E, LFTs, CMP, and blood cultures. Creatinine kinase >5x ULN is diagnostic. Management follows the STOP framework: Sepsis evaluation, Toxin discontinuation, Output/Input monitoring, and Potassium management. Aggressive rehydration is the mainstay ('solution to pollution is dilution'). Hyperkalemia requires three steps: calcium gluconate for cardiac stabilization, insulin/dextrose for intracellular shift, and potassium binders for elimination. Additional electrolyte management includes phosphate binders and calcium replacement. Dialysis is reserved for severe cases.

Rhabdomyolysis causes AKI through three mechanisms: (1) vasoconstriction via prostaglandins, endothelin-1, and thromboxane A2 activation of renin-angiotensin-aldosterone system, (2) oxidative injury from hemoglobin binding to tubular proteins causing iron accumulation and Fenton reaction generating free radicals, and (3) obstruction by myoglobin-haptoglobin complexes forming casts in distal tubules. The muscle lesion becomes a third space, perpetuating hypoperfusion. Clinical presentation varies with severity: only 10% present with classic triad (myalgia, weakness, dark urine). Most common symptoms: myalgia (80%), weakness (70%), dark urine (5%). Pediatric patients may present with fever, abdominal pain, nausea, and vomiting. Cardiovascular complications arise from hyperkalemia. Oliguria/anuria are critical symptoms requiring immediate intervention.

Treatment for severe rhabdomyolysis focuses on aggressive IV fluid administration to flush toxins from the kidneys and prevent renal failure. Patients typically receive fluids at rates of 1,000-1,250 ml/hour initially, maintaining urine output above 250 ml/hour. Continuous monitoring of kidney function through creatinine and BUN levels is essential. Prognosis improves significantly when kidney function remains stable during initial presentation. Recovery requires patience and continued treatment until CK levels drop below 8,000-12,000 U/L, typically taking several days to weeks.